Two Seas Capital LP Buys 353,568 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Two Seas Capital LP lifted its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 4.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,740,956 shares of the biopharmaceutical company's stock after purchasing an additional 353,568 shares during the period. Arbutus Biopharma comprises approximately 2.5% of Two Seas Capital LP's holdings, making the stock its 11th biggest holding. Two Seas Capital LP owned 4.61% of Arbutus Biopharma worth $28,583,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Arbutus Biopharma by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company's stock valued at $29,367,000 after buying an additional 62,282 shares in the last quarter. Geode Capital Management LLC boosted its position in Arbutus Biopharma by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company's stock worth $11,390,000 after purchasing an additional 33,536 shares during the period. BlackBarn Capital Partners LP increased its holdings in Arbutus Biopharma by 13.1% in the 4th quarter. BlackBarn Capital Partners LP now owns 2,341,871 shares of the biopharmaceutical company's stock valued at $7,658,000 after purchasing an additional 270,971 shares in the last quarter. Rangeley Capital LLC purchased a new position in Arbutus Biopharma in the fourth quarter valued at about $4,771,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Arbutus Biopharma by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,222,201 shares of the biopharmaceutical company's stock worth $3,997,000 after purchasing an additional 9,955 shares in the last quarter. Hedge funds and other institutional investors own 43.79% of the company's stock.

Arbutus Biopharma Trading Up 5.9 %

ABUS stock traded up $0.20 during trading hours on Wednesday, hitting $3.61. 561,237 shares of the stock traded hands, compared to its average volume of 989,798. The stock has a 50-day simple moving average of $3.28 and a 200 day simple moving average of $3.44. Arbutus Biopharma Co. has a one year low of $2.63 and a one year high of $4.73. The company has a market cap of $691.24 million, a P/E ratio of -8.40 and a beta of 1.45.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The business had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Analysts forecast that Arbutus Biopharma Co. will post -0.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ABUS. StockNews.com upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 29th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a report on Tuesday, January 21st. Finally, Chardan Capital restated a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.